A number of other research analysts have also recently weighed in on the stock. BidaskClub cut shares of Zai Lab from a buy rating to a hold rating in a report on Thursday, September 5th. Macquarie assumed coverage on shares of Zai Lab in a report on Friday, July 5th. They issued an outperform rating and a $36.54 price objective for the company. China Renaissance Securities assumed coverage on shares of Zai Lab in a report on Wednesday, September 4th. They issued a buy rating for the company. Leerink Swann set a $48.00 price objective on shares of Zai Lab and gave the company a buy rating in a report on Wednesday, September 4th. Finally, Bank of America assumed coverage on shares of Zai Lab in a report on Friday, July 12th. They issued a buy rating and a $43.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Zai Lab has an average rating of Buy and an average price target of $42.87.
ZLAB traded up $0.51 on Wednesday, reaching $32.56. The stock had a trading volume of 74,547 shares, compared to its average volume of 195,519. Zai Lab has a 12-month low of $14.29 and a 12-month high of $38.44. The business’s 50-day moving average price is $33.94 and its two-hundred day moving average price is $31.63. The company has a market cap of $1.89 billion, a P/E ratio of -12.33 and a beta of 1.32.
Zai Lab Company Profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Article: What is the float in trading stocks?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.